EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024)

Sara Sultan, Ruba A Zenati, Hanan S Anbar iD, Mohammed I El-Gamal iD, Mohammad H Semreen iD

ChemMedChem · 18.07.2025 · 20 (14)

DOI: 10.1002/cmdc.202500279 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 20.06.2025. Verfasst von Sara Sultan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates. Hauptthemen laut MEDLINE: Quinolines, Protein Kinase Inhibitors, Small Molecule Libraries, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 229 Literaturangaben. Gefördert von: University of Sharjah.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quinoline‐containing compounds have gained prominence in drug discovery as versatile scaffolds. These compounds have shown promise in the development of kinase inhibitors, which are crucial treatment options used in various cancer cases. This review explores the recent advances from 2020 to 2024 in the design, synthesis, and optimization of quinoline‐based kinase inhibitors, focusing on their role in targeting key kinases, implicated in cancer signaling pathways. Quinoline derivatives exhibit significant inhibitory activity across a broad spectrum of kinases, highlighting their potential to disrupt aberrant signaling that drives tumor growth and progression. Several FDA‐approved quinoline‐containing compounds are utilized in clinical settings as kinase inhibitors, reinforcing their importance and relevance in clinical oncology. This review compiles the pharmacological profiles of these inhibitors spotlighting key compounds that have demonstrated potent inhibitory activities, excellent selectivity profiles, and promising preclinical or clinical outcomes. The review also addresses the challenges associated with their development and discusses future directions for optimizing quinoline‐based kinase inhibitors, such as leveraging advanced drug design techniques, exploring novel targets, and expanding their use in combination therapies. By summarizing recent advancements, this review aims to provide insights into the evolving landscape of quinoline‐based kinase inhibitors and their potential as next‐generation anticancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesProtein Kinase InhibitorsSmall Molecule LibrariesAntineoplastic AgentsHumansNeoplasmsMolecular StructureStructure-Activity RelationshipAnimals

Stichwörter der Autor:innen

anticancerkinase inhibitorskinasesquinoline derivatives

Substanzen

QuinolinesProtein Kinase InhibitorsSmall Molecule LibrariesAntineoplastic Agentsquinoline

Autor:innen und Institutionen

  • Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • Department of Pharmaceutical Sciences, Dubai Pharmacy College for Girls, Dubai Medical University, Dubai, 19099, United Arab Emirates.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.

ORCID-Profile: Hanan S Anbar, Mohammed I El-Gamal, Mohammad H Semreen

Förderung

  • University of Sharjah

Zitieren

APA

Sultan, S., Zenati, R. A., Anbar, H. S., El-Gamal, M. I., & Semreen, M. H. (2025). Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024). ChemMedChem, 20(14). https://doi.org/10.1002/cmdc.202500279

Vancouver

Sultan S, Zenati RA, Anbar HS, El-Gamal MI, Semreen MH. Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024). ChemMedChem. 2025;20(14). doi:10.1002/cmdc.202500279

BibTeX
@article{Sultan2025,
  author = {Sultan, Sara and Zenati, Ruba A and Anbar, Hanan S and El-Gamal, Mohammed I and Semreen, Mohammad H},
  title = {Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024)},
  journal = {ChemMedChem},
  year = {2025},
  volume = {20},
  number = {14},
  doi = {10.1002/cmdc.202500279}
}
Kostenlos starten →